-
Electronic (PDF)
-
Site License
-
Enterprisewide
Menopausal Disorders - Pipeline Review, Q4 2010
Global Markets Direct, December 2010, Pages: 40
Menopausal Disorders - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Menopausal Disorders Pipeline Review, Q4 2010”, provides an overview of the Menopausal Disorders therapeutic pipeline. This report provides information on the therapeutic development for Menopausal Disorders , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Menopausal Disorders . “Menopausal Disorders -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Menopausal Disorders .
- A review of the Menopausal Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for Menopausal Disorders .
- A review of the Menopausal Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Menopausal Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Menopausal Disorders Overview
Therapeutics Development
An Overview of Pipeline Products for Menopausal Disorders
Menopausal Disorders Therapeutics under Development by Companies
Menopausal Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Menopausal Disorders Therapeutics Development
Chiesi Farmaceutici SpA
Pfizer Inc.
Bayer AG
Paladin Labs Inc.
Bionovo, Inc.
Meditrina Pharmaceuticals, Inc.
Universities/Institutes Involved in Menopausal Disorders Therapeutics Development
Menopausal Disorders Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Angeliq low-low - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprela - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + goserelin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pristiq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
GnRH agonist - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isoflavone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Menopausal Disorders - Featured News
May 20, 2010: Novo Nordisk's Vagifem 10mcg To Replace Vagifem 25mcg Formulation For Atrophic Vaginitis
Dec 14, 2009: Ablynx Initiates Phase I Trial Study Of ALX-0141 For The Treatment Of Postmenopausal Women
Sep 03, 2009: Bionovo To Present Positive Results From Phase 2 Trial Of Menerba For Vasomotor Symptoms To The International Community
Dec 21, 2006: Pherin Pharmaceuticals Reports Favorable Phase II Data Showing Clinical Benefits of Novel Intranasal Medication PH80 to Treat Symptoms of Premenstrual Syndrome (PMS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
